Life Sciences Times, Author at Boston Life Sciences Times

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

March 10, 2026

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

March 5, 2026

Arsenal Medical Treats First Patient with ResQFoam Device for Life-Threatening Abdominal Bleeding

March 4, 2026

THIS WEEK'S STORIES

Physicians Increasingly Concerned About Affordable Healthcare Access, athenahealth Survey Finds

March 4, 2026

Affinia Therapeutics Receives FDA Fast Track Designation for AFTX-201 Gene Therapy for BAG3-Associated Dilated Cardiomyopathy

March 4, 2026

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

March 10, 2026

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

Qlaris Bio Appoints Fred Guerard, Pharm.D., as President and Chief Executive Officer

IFAW Urges Science-Based Conservation as Debate Over African Elephant Populations Intensifies

WHOOP Expands Health Platform with Women’s Blood Biomarker Panel and New Cycle Insights Tools

Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board

EDITOR PICKS

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

Arsenal Medical Treats First Patient with ResQFoam Device for Life-Threatening Abdominal Bleeding

THIS WEEK'S STORIES

Physicians Increasingly Concerned About Affordable Healthcare Access, athenahealth Survey Finds

Affinia Therapeutics Receives FDA Fast Track Designation for AFTX-201 Gene Therapy for BAG3-Associated Dilated Cardiomyopathy

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

POPULAR CATEGORY

ABOUT US

FOLLOW US